Optogenetics and its application in pain and anxiety research

Jarrin, Sarah; Finn, David P.

doi:10.1016/j.neubiorev.2019.08.007

Cited by 21 publications

(19 citation statements)

References 126 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The study of neuropathic pain processes with the use of the pharmacological stimulation remains a valid approach, although it shows some deficits such as the lack of specificity when targeting a specific brain region or a specific neurotransmission. This represent a big limitation in the study of the neuronal/neural circuitry involved in the pathophysiology of neuropathic pain [121]. For instance, spatially specifically targeted strategies to modulate and to study the physiology of neuropathic pain have been developed and they could ultimately represent such a good tool to help science and clinical pain management.…”

Section: Cutting-edge Techniques In Sni Model: Focus On Optogenetic Amentioning

confidence: 99%

Behavioral, Biochemical and Electrophysiological Changes in Spared Nerve Injury Model of Neuropathic Pain

Guida¹,

Gregorio

Palazzo³

et al. 2020

IJMS

View full text Add to dashboard Cite

Neuropathic pain is a pathological condition induced by a lesion or disease affecting the somatosensory system, with symptoms like allodynia and hyperalgesia. It has a multifaceted pathogenesis as it implicates several molecular signaling pathways involving peripheral and central nervous systems. Affective and cognitive dysfunctions have been reported as comorbidities of neuropathic pain states, supporting the notion that pain and mood disorders share some common pathogenetic mechanisms. The understanding of these pathophysiological mechanisms requires the development of animal models mimicking, as far as possible, clinical neuropathic pain symptoms. Among them, the Spared Nerve Injury (SNI) model has been largely characterized in terms of behavioral and functional alterations. This model is associated with changes in neuronal firing activity at spinal and supraspinal levels, and induces late neuropsychiatric disorders (such as anxious-like and depressive-like behaviors, and cognitive impairments) comparable to an advanced phase of neuropathy. The goal of this review is to summarize current findings in preclinical research, employing the SNI model as a tool for identifying pathophysiological mechanisms of neuropathic pain and testing pharmacological agent.

show abstract

Section: Cutting-edge Techniques In Sni Model: Focus On Optogenetic Amentioning

confidence: 99%

Behavioral, Biochemical and Electrophysiological Changes in Spared Nerve Injury Model of Neuropathic Pain

Guida¹,

Gregorio

Palazzo³

et al. 2020

IJMS

View full text Add to dashboard Cite

show abstract

“…Another disease awaiting the approval of initial clinical trials involving the application of optogenetic therapy and for which existing methods of treatment show limited effectiveness is urinary bladder syndrome [5]. Furthermore, many optogenetic studies conducted on animal models, such as rodents or nonhuman primates [6], were designed with the explicit goal of developing better targeted brain stimulation treatments for various psychiatric and neurological disorders in humans [7][8][9][10][11][12][13][14]. These attempts, along with rapid advancements in the field, demonstrate that optogenetics is already progressing towards clinical application.…”

Section: The Need For Further Neuroethical Debatementioning

confidence: 99%

“…These attempts, along with rapid advancements in the field, demonstrate that optogenetics is already progressing towards clinical application. Moreover, some (e.g., [9,11,15]) argue that it could also become an alternative form of therapy to deep brain stimulation (DBS), another form of invasive neuromodulation technology, 4 which, over the past decade, has become a widely accepted treatment method for patients struggling with different types of disorders. However, it is worth mentioning that both methods seem to be developing in parallel: while some scientists are putting their efforts into refining DBS to gain greater, optogenetic-like precision in targeting specific brain structures [19], others are trying to "refine" optogenetics to make it less invasive and to enhance its potential as a future treatment [20].…”

Section: The Need For Further Neuroethical Debatementioning

confidence: 99%

“…Some of the most basic ethical issues (such as efficacy and safety concerns) associated with the application of optogenetics to humans have already begun to be addressed [21][22][23][24][25]. However, as optogenetics is being intensively investigated in the context of the development of effective brain stimulation treatments for various neurological and psychiatric disorders such as depression [8], schizophrenia [10,13], anxiety and pain [11], movement disorders [14], including Parkinson's disease [9,65], addictions [90], epilepsy [91], and memory-related disorders such as PTSD [12], diencephalic amnesia, and Alzheimer's disease [7], it is conceivable that optogenetics or other optogenetic-like neurostimulation methods (that allow for a similar degree of neural specificity and precision, will eventually be used to apply these findings as a form of therapy in humans. And, indeed, some optogenetics findings regarding characterization of neural circuits and their dysfunction in various brain diseases are currently inspiring novel stimulation protocols that are planned to be applied as a form of treatment in humans by means of refined DBS [92].…”

Section: Call For a Debate On The Neuroethical Consequences Of The Mementioning

confidence: 99%

“…As long as prognostic indicators of the development of psychological disorders such as PTSD in the immediate aftermath of trauma are not fully developed, MMTs that rely on intervention within the consolidation window take the risk that the patient will be deprived of the opportunity to attempt recovery from trauma on his or her own through an appeal to rational capacities, for example via the construction of a redemptive story to promote posttraumatic growth [95]. 11 On the other hand, as some MMTs (e.g., propranolol, optogenetics) have the potential to modify even well-consolidated memories, this opportunity may reduce the above ethical concern through the introduction of legal regulations mandating that only memories contributing to the development of a particular trauma are to be treated (see also [53]).…”

Section: The Issue Of "Natural" Recovery From Traumatic Experiencesmentioning

confidence: 99%

See 2 more Smart Citations

The Memory-Modifying Potential of Optogenetics and the Need for Neuroethics

Adamczyk

Zawadzki

2020

Nanoethics

View full text Add to dashboard Cite

Optogenetics is an invasive neuromodulation technology involving the use of light to control the activity of individual neurons. Even though optogenetics is a relatively new neuromodulation tool whose various implications have not yet been scrutinized, it has already been approved for its first clinical trials in humans. As optogenetics is being intensively investigated in animal models with the aim of developing novel brain stimulation treatments for various neurological and psychiatric disorders, it appears crucial to consider both the opportunities and dangers such therapies may offer. In this review, we focus on the memory-modifying potential of optogenetics, investigating what it is capable of and how it differs from other memory modification technologies (MMTs). We then outline the safety challenges that need to be addressed before optogenetics can be used in humans. Finally, we re-examine crucial neuroethical concerns expressed in regard to other MMTs in the light of optogenetics and address those that appear to be unique to the memory-modifying potential of optogenetic technology.

show abstract

Emerging Biomedical Applications of Organic Light‐Emitting Diodes

Murawski

Gather

2021

Advanced Optical Materials

View full text Add to dashboard Cite

As solid‐state light sources based on amorphous organic semiconductors, organic light‐emitting diodes (OLEDs) are widely used in modern smartphone displays and TVs. Due to the dramatic improvements in stability, efficiency, and brightness achieved over the last three decades, OLEDs have also become attractive light sources for compact and “imperceptible” biomedical devices that use light to probe, image, manipulate, or treat biological matter. The inherent mechanical flexibility of OLEDs and their compatibility with a wide range of substrates and geometries are of particular benefit in this context. Here, recent progress in the development and use of OLEDs for biomedical applications is reviewed. The specific requirements that this poses are described and compared to the current state of the art, in particular in terms of the brightness, patterning, stability, and encapsulation of OLEDs. Examples from several main areas are then discussed in some detail: on‐chip sensing and integration with microfluidics, wearable devices for optical monitoring, therapeutic devices, and the emerging use in neuroscience for targeted photostimulation via optogenetics. The review closes with a brief outlook on future avenues to scale the manufacturing of OLED‐based devices for biomedical use.

show abstract

Optogenetics and its application in pain and anxiety research

Cited by 21 publications

References 126 publications

Behavioral, Biochemical and Electrophysiological Changes in Spared Nerve Injury Model of Neuropathic Pain

Behavioral, Biochemical and Electrophysiological Changes in Spared Nerve Injury Model of Neuropathic Pain

The Memory-Modifying Potential of Optogenetics and the Need for Neuroethics

Emerging Biomedical Applications of Organic Light‐Emitting Diodes

Contact Info

Product

Resources

About